Stoke Therapeutics, Inc. - STOK STOCK NEWS

Stoke Therapeutics announced the enrollment of the first patient in its FALCON study, focusing on autosomal dominant optic atrophy (ADOA), a rare genetic disorder causing severe vision loss. The study aims to evaluate disease progression and support the development of STK-002, a potential therapy targeting the underlying cause of ADOA. ADOA affects approximately one in 30,000 people globally, with no approved treatments currently available. The FALCON study will enroll about 45 patients across 10 sites in the U.S., U.K., Italy, and Denmark.

Stoke Therapeutics (Nasdaq: STOK) reported its Q2 2022 financial results, showing revenue of $3.2 million from a License and Collaboration Agreement, compared to none in 2021. The net loss for the quarter was $24.7 million, with R&D expenses rising to $18.4 million. The company has approximately $276.2 million in cash, expected to fund operations into 2025. In Q4, interim data from clinical studies on STK-001 in Dravet syndrome will be announced, focusing on safety and seizure frequency. Additionally, STK-002 received FDA orphan drug designation for Autosomal Dominant Optic Atrophy.

Stoke Therapeutics (Nasdaq: STOK) announced its participation in the 2022 Jefferies Healthcare Conference on June 8, 2022, at 4:00 p.m. ET. The presentation will be in a fireside chat format, accessible via a live webcast through Stoke's Investors & News section. Stoke focuses on RNA-based medicines to address severe diseases, with their first compound, STK-001, in clinical testing for Dravet syndrome. For more info, visit stoke therapeutics.

Stoke Therapeutics reported financial results for Q1 2022, with a net loss of $24.6 million, or $0.66 per share, compared to $16.8 million, or $0.46 per share, in Q1 2021.

The company continues to advance STK-001 in clinical trials for Dravet syndrome, with data readouts expected in 2H 2022. They also announced progress in developing STK-002 for Autosomal Dominant Optic Atrophy (ADOA) and have $293.8 million in cash to fund operations through 2025.

Stoke Therapeutics presented promising preclinical data at the ARVO Annual Meeting, showcasing STK-002 as a potential disease-modifying treatment for Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder. The data revealed sustained increases in OPA1 protein levels in the retinal tissue of non-human primates following intravitreal administration of STK-002. Significant protein increases were observed even up to eight weeks post-injection, demonstrating the drug's potential to address the underlying cause of ADOA, which affects roughly 1 in 30,000 globally.

Stoke Therapeutics (Nasdaq: STOK) announced new preclinical data supporting the development of STK-002 for treating autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. This proprietary antisense oligonucleotide is designed to increase OPA-1 protein expression to halt or reverse vision loss. The findings will be presented at the ARVO 2022 Annual Meeting in Denver from May 1-4, 2022. Currently, ADOA affects approximately one in 30,000 people globally, with no approved treatment available.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA-based medicines, will present at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:00 a.m. ET. The presentation will be in a fireside chat format, available via live webcast on Stoke's website. Stoke aims to address severe diseases by upregulating protein expression using its proprietary TANGO approach. Their lead compound, STK-001, is in clinical testing for Dravet syndrome, while STK-002 targets autosomal dominant optic atrophy.

Stoke Therapeutics, Inc. (Nasdaq: STOK) reported a net loss of $85.8 million for 2021, reflecting an increase in research and development expenses to $54.2 million. The company continues to advance its clinical pipeline, including ongoing Phase 1/2a studies for STK-001 in treating Dravet syndrome and preclinical studies for STK-002 targeting Autosomal Dominant Optic Atrophy (ADOA). With $220.4 million in cash and a recent $60 million collaboration with Acadia Pharmaceuticals, Stoke is positioned to fund operations through mid-2024 and share additional clinical data in 2H 2022.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm focused on RNA-based therapies for severe diseases, will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event will be accessible via a live webcast on their official website, with a replay available for 30 days. Stoke utilizes its innovative TANGO approach to develop targeted treatments, such as STK-001 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy. The company is headquartered in Bedford, Massachusetts.